Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
Evaluation of 2 doses of rivaroxaban (10 and 15 mg) compared to dual anti platelet therapy (aspirin+clopidogrel) after left atrial appendage closure. The patients will be assessed at 10 and 90 days: central laboratory hemostasis analysis and clinical events assessment.
Epistemonikos ID: 0521dbffff886542d7b7fb35596fc77289f1e4f8
First added on: May 21, 2024